Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

1.360 +0.030 (+2.26%)
Streaming Delayed Price Updated: 9:46 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
BioRestorative (BRTX) Earnings Call Transcript ↗
BioRestorative (BRTX) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Economy Intellectual Property
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For BioRestorative Therapies ↗
 
Via Benzinga
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
Unusual volume stocks are being observed in Tuesday's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Outlook For BioRestorative Therapies ↗
 
Via Benzinga
News headline image
Earnings Preview For BioRestorative Therapies ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain
Via TheNewswire.com
News headline image
BioRestorative Announces Share Repurchase Program
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based 
Via PressReach
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based 
Via PressReach
News headline image
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based 
Via PressReach
News headline image
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based 
Via PressReach
News headline image
Uncovering Potential: BioRestorative Therapies's Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
Via TheNewswire.com
News headline image
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
By Meg Flippin Benzinga 
Via TheNewswire.com
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
Which stocks have an unusual volume on Thursday? ↗
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial 
Via News Direct
Topics Intellectual Property
News headline image
Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market
Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market 
Via News Direct
Topics Intellectual Property
News headline image
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function ↗
BioRestorative Therapies shares promising Phase 2 trial results for BRTX-100, showing significant pain reduction and functional improvement in cLDD patients. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.